Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
ZYDUS LIFESCIENCES ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ZYDUS LIFESCIENCES Mar-23 |
ADCOCK INGRAM Jun-14 |
ZYDUS LIFESCIENCES/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 495 | 320 | - | |
Low | Rs | 319 | 231 | - | |
Sales per share (Unadj.) | Rs | 170.3 | 95.3 | - | |
Earnings per share (Unadj.) | Rs | 19.8 | -24.0 | - | |
Cash flow per share (Unadj.) | Rs | 26.9 | -19.9 | - | |
Dividends per share (Unadj.) | Rs | 6.00 | 0 | - | |
Avg Dividend yield | % | 1.5 | 0 | - | |
Book value per share (Unadj.) | Rs | 173.0 | 74.8 | - | |
Shares outstanding (eoy) | m | 1,012.20 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.4 | 2.9 | 82.6% | |
Avg P/E ratio | x | 20.6 | -11.5 | -179.3% | |
P/CF ratio (eoy) | x | 15.1 | -13.9 | -109.2% | |
Price / Book Value ratio | x | 2.4 | 3.7 | 63.8% | |
Dividend payout | % | 30.3 | 0 | - | |
Avg Mkt Cap | Rs m | 412,144 | 46,551 | 885.4% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 24,564 | 2,922 | 840.8% | |
Avg. sales/employee | Rs Th | 0 | 3,747.7 | - | |
Avg. wages/employee | Rs Th | 0 | 680.6 | - | |
Avg. net profit/employee | Rs Th | 0 | -944.3 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 172,374 | 16,089 | 1,071.4% | |
Other income | Rs m | 4,746 | 113 | 4,212.5% | |
Total revenues | Rs m | 177,120 | 16,201 | 1,093.2% | |
Gross profit | Rs m | 29,677 | -2,788 | -1,064.4% | |
Depreciation | Rs m | 7,227 | 694 | 1,040.8% | |
Interest | Rs m | 1,299 | 436 | 298.1% | |
Profit before tax | Rs m | 25,897 | -3,806 | -680.5% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 5,878 | 238 | 2,471.9% | |
Profit after tax | Rs m | 20,019 | -4,054 | -493.8% | |
Gross profit margin | % | 17.2 | -17.3 | -99.3% | |
Effective tax rate | % | 22.7 | -6.2 | -363.2% | |
Net profit margin | % | 11.6 | -25.2 | -46.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 100,082 | 11,784 | 849.3% | |
Current liabilities | Rs m | 55,267 | 6,630 | 833.6% | |
Net working cap to sales | % | 26.0 | 32.0 | 81.2% | |
Current ratio | x | 1.8 | 1.8 | 101.9% | |
Inventory Days | Days | 50 | 111 | 45.4% | |
Debtors Days | Days | 94 | 124 | 75.5% | |
Net fixed assets | Rs m | 144,776 | 6,869 | 2,107.8% | |
Share capital | Rs m | 1,012 | 75 | 1,354.8% | |
Net worth | Rs m | 175,158 | 12,628 | 1,387.1% | |
Long term debt | Rs m | 0 | 4,438 | 0.0% | |
Total assets | Rs m | 244,940 | 23,855 | 1,026.8% | |
Interest coverage | x | 20.9 | -7.7 | -270.8% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.7 | 0.7 | 104.3% | |
Return on assets | % | 8.7 | -15.2 | -57.4% | |
Return on equity | % | 11.4 | -32.1 | -35.6% | |
Return on capital | % | 15.5 | -19.8 | -78.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 26,888 | 1,373 | 1,957.9% | |
From Investments | Rs m | 11,712 | -422 | -2,777.5% | |
From Financial Activity | Rs m | -44,004 | 4,028 | -1,092.6% | |
Net Cashflow | Rs m | -5,338 | 4,979 | -107.2% |
Compare ZYDUS LIFESCIENCES With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare ZYDUS LIFESCIENCES With: ALEMBIC MARKSANS PHARMA. GENNEX LAB. VENUS REMEDIES BHARAT PARENTALS
On Monday, Indian share markets reversed the trend as the session progressed and ended the day higher.